Please enable JavaScript.
Coggle requires JavaScript to display documents.
Hypersensitivity and Immunosuppression - Coggle Diagram
Hypersensitivity and Immunosuppression
Allergy
Immune response to normally innocuous antigen
Sensitisation
Supsequent re-exposure - stronger response
Hypersensitivity
Excessive or inappropropriate activation of the immue system
Types
I, II, III
Antibody dependant
Evident within hours
Immediate hypersensitivities
IV
Mediated by T-cells and cytokines
Requires a day to develop
Delayed sensitivity
Types 1
Antibody mediated (IgE dependent)
Pathogenesis
Degranulation with
Antigen binds to antibody on surface of mast cells
Managment
Atopy
Anapylaxis
Type 2
Type 3
Type 4
Histamine
Receptors (4)
Antihistamines (H-1 inverse agonists)
MOA
Pharmacokinetics
Side Effects
Types
1st gen
Diphenhydramins
Chlorpheniramine (Piriton)
Cyclizine
Promethazine (Phenergan)
2nd gen
Cetirizine (Zyrtec)
Fexofenadine (Telfasts)
Loratadine (Neoclarityn)
Mast Cell Stabilisers
Drugs
Sodium Chromoglycaste
MOA
SE
Indications
Inhaler prevention of acute asthma
Anaphylaxis
Protocol
Community
Hospital
Definition
Pathogenesis
Signs / Symptoms
Causes
Medication Safety
Glucocorticoids
MOA
Pharmacokinetics
SE
Metabolic
CVS
MSK
Neuropsychiatric
GI
Skin
renal
Eye
HPA axis
Immunosuppressants
Indications
Defintion
Types
